文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

可调控白介素-12基因治疗复发高级别胶质瘤患者的1期试验结果

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
PubMed 文献 · Sci Transl Med · 2019-01-01

多中心1期剂量递增试验纳入31例复发高级别胶质瘤切除术患者,瘤腔壁注射固定剂量Ad-RTS-hIL-12载体,口服veledimex调控hIL-12表达。veledimex剂量与不良事件相关,20 mg组中位总生存12.7个月,同期使用地塞米松累计>20 mg者生存更差。

要点

  • 瘤腔壁注射Ad-RTS-hIL-12后口服veledimex可调控hIL-12表达,外周血IL-12和IFN-γ随veledimex剂量增加。
  • veledimex 20 mg组中位总生存12.7个月(平均随访13.1个月)。
  • 地塞米松累计>20 mg(第0-14天)者中位总生存6.4个月,≤20 mg者16.7个月。

核心结论

  • 该1期试验显示调控性hIL-12耐受性可接受,并取得令人鼓舞的初步结果。
  • 再切除标本显示主要为假性进展,伴产生IFN-γ和PD-1的肿瘤浸润淋巴细胞增多,支持hIL-12的免疫抗肿瘤效应。

研究设计与样本

  • 多中心1期剂量递增试验(NCT02026271),31例复发高级别胶质瘤切除术患者。
  • 第0天向切除腔壁注射固定剂量Ad-RTS-hIL-12载体,术前和术后口服veledimex,队列接受10至40 mg veledimex。

主要发现

  • 外周血中veledimex、IL-12和IFN-γ呈剂量相关增加,veledimex肿瘤穿透率约40%。
  • 不良事件(包括细胞释放综合征)的频率和严重程度与veledimex剂量相关,停药后迅速逆转。
  • veledimex 20 mg组药物依从性更优,平均随访13.1个月时中位总生存为12.7个月。
  • 地塞米松累计>20 mg(第0-14天)vs ≤20 mg:全部患者中位总生存6.4 vs 16.7个月;20 mg veledimex队列中为6.4 vs 17.8个月。
  • Ad-RTS-hIL-12后疑似复发的5例中5例再切除,显示主要为假性进展,伴产生IFN-γ和PD-1的肿瘤浸润淋巴细胞增多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic application is limited by toxic inflammatory responses. We assessed the safety and biological effects of an hIL-12 gene, transcriptionally regulated by an oral activator. A multicenter phase 1 dose-escalation trial (NCT02026271) treated 31 patients undergoing resection of recurrent high-grade glioma. Resection cavity walls were injected (day 0) with a fixed dose of the hIL-12 vector (Ad-RTS-hIL-12). The oral activator for hIL-12, veledimex (VDX), was administered preoperatively (assaying blood-brain barrier penetration) and postoperatively (measuring hIL-12 transcriptional regulation). Cohorts received 10 to 40 mg of VDX before and after Ad-RTS-hIL-12. Dose-related increases in VDX, IL-12, and interferon-γ (IFN-γ) were observed in peripheral blood, with about 40% VDX tumor penetration. Frequency and severity of adverse events, including cytokine release syndrome, correlated with VDX dose, reversing promptly upon discontinuation. VDX (20 mg) had superior drug compliance and 12.7 months median overall survival (mOS) at mean follow-up of 13.1 months. Concurrent corticosteroids negatively affected survival: In patients cumulatively receiving >20 mg versus ≤20 mg of dexamethasone (days 0 to 14), mOS was 6.4 and 16.7 months, respectively, in all patients and 6.4 and 17.8 months, respectively, in the 20-mg VDX cohort. Re-resection in five of five patients with suspected recurrence after Ad-RTS-hIL-12 revealed mostly pseudoprogression with increased tumor-infiltrating lymphocytes producing IFN-γ and programmed cell death protein 1 (PD-1). These inflammatory infiltrates support an immunological antitumor effect of hIL-12. This phase 1 trial showed acceptable tolerability of regulated hIL-12 with encouraging preliminary results.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019. PMID: 31413142. doi:10.1126/scitranslmed.aaw5680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。